Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.

MLA

Douglas, Raymond S., et al. “Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.” The Journal of Clinical Endocrinology and Metabolism, vol. 109, no. 1, Dec. 2023, pp. 25–35. EBSCOhost, https://doi.org/10.1210/clinem/dgad637.

APA

Douglas, R. S., Couch, S., Wester, S. T., Fowler, B. T., Liu, C. Y., Subramanian, P. S., Tang, R., Nguyen, Q. T., Maamari, R. N., Ugradar, S., Hsu, K., Karon, M., & Stan, M. N. (2023). Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology and Metabolism, 109(1), 25–35. https://doi.org/10.1210/clinem/dgad637

Chicago

Douglas, Raymond S, Steven Couch, Sara T Wester, Brian T Fowler, Catherine Y Liu, Prem S Subramanian, Rosa Tang, et al. 2023. “Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.” The Journal of Clinical Endocrinology and Metabolism 109 (1): 25–35. doi:10.1210/clinem/dgad637.